© 2021 MJH Life Sciences and Cure Today. All rights reserved.
© 2021 MJH Life Sciences™ and Cure Today. All rights reserved.
June 18th 2021, 3:00pm
From a man with late-stage cancer who has matching tattoos with over 400 strangers to a 78-year-old cancer survivor getting his black belt in Taekwondo, here’s what’s happening in the cancer landscape this week.
June 10th 2021, 6:00pm
Use of the combination of Keytruda and Inlyta is associated with long-term survival benefits in patients with kidney cancer.
June 6th 2021, 6:00pm
In patients with metastatic renal cell carcinoma who have failed on two prior therapies, Fotivda, compared with Nexavar, contributed to a duration of response of 20.3 months versus 9 months.
June 4th 2021, 6:30pm
Treatment with Keytruda following surgery was associated with a significant reduction in the risk of disease recurrence or death compared with placebo in patients with clear cell renal cell carcinoma.
May 6th 2021, 1:52pm
The priority review will focus on the combination of Keytruda and Lenvima for the first-line treatment of advanced renal cell carcinoma, as well as the treatment of certain patients with endometrial carcinoma.
April 22nd 2021, 6:00pm
Recent data found an association between higher BMI and better overall survival among patients with metastatic renal cell carcinoma who were treated with immune checkpoint inhibitors.
April 20th 2021, 9:00pm
Certain patients with metastatic renal cell carcinoma may benefit with active surveillance compared with systemic therapy for their management and may also lead to an improved quality of life.
April 19th 2021, 1:00pm
Inlyta alone demonstrates longer progression-free survival compared to Inlyta in combination with carotuximab.
April 9th 2021, 1:00pm
CURE spoke with Dr. Eric Jonasch about the National Comprehensive Cancer Network’s Category 1 recommendation for the combination use of Lenvima plus Keytruda for the treatment of front-line renal cell carcinoma. In particular, how it can impact a patient’s treatment journey.
March 24th 2021, 6:00pm
The biggest reason the FDA’s recent approval of Fotivda is important for adults with relapsed or refractory advanced renal cell carcinoma who have received two or more prior systemic therapies, according to an expert from the Vanderbilt-Ingram Cancer Center, is that it offers them a very tolerable treatment option that may preserve quality of life.
A Milkshake and Metastatic Cancer
Fighting Hard for Patients with Fibrolamellar Carcinoma
Masking in a ‘Post-Pandemic’ World
A Guardian Angel Among Doctors